The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes
    • The Product Book

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
    • Content Hubs
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2026 / November / Unlocking the Multi-Omics Potential of a Blood Spot
Omics Omics Mass Spectrometry Liquid Chromatography

Unlocking the Multi-Omics Potential of a Blood Spot

Combining metabolite and lipid analysis could help researchers uncover more biochemical information from a single dried blood sample

By Jessica Allerton 11/20/2026 3 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Report: Unlocking the Multi-Omics Potential of a Blood Spot

Overview

Timothy Garrett and Esabella Powers describe a protocol for extracting metabolites and lipids from one 10 µL dried blood spot (DBS) for analysis by liquid chromatography–high-resolution tandem mass spectrometry (LC-HRMS/MS). The approach addresses the limited sample volume and differing chemical properties of the two molecular classes, but further development and clinical validation are needed to assess its potential for broader newborn screening and diagnostic use.

Background

DBS are used in newborn screening to identify conditions, including inborn errors of metabolism, through measurement of specific metabolites. Their low-volume collection and practical storage and transport have also supported research across multiple molecular classes. However, most DBS workflows analyze one molecular class at a time, limiting the biochemical information obtained from a small or irreplaceable specimen. Measuring metabolites and lipids from the same spot is intended to broaden the profile available for research.

Data Highlights

AspectReported details
SampleSingle 10 µL volumetric DBS
ExtractionBiphasic extraction modeled on the Folch method; lipids partition into the organic phase and metabolites into the aqueous phase
AnalysisLC-HRMS/MS; metabolite processing in MZmine and lipid annotation using LipidMatch
Reliability assessmentMultiple extractions from the same donors on different days were compared
Pre-analytical considerationsSpecimen matrix, drying and storage, hematocrit, and spot volume can affect measured profiles

Key Findings

  • The protocol extracts metabolites and lipids from one DBS, enabling both molecular classes to be analyzed from the same sample.
  • A biphasic extraction was used to accommodate the different chemical properties of polar metabolites and lipids.
  • A lower reconstitution volume was used to concentrate analytes and improve signal intensity; glass pipettes and tubes were used to minimize polyethylene glycol contamination.
  • Metabolites were processed in MZmine and identified through MS/MS spectral matching and an in-house LC-MS library based on mass-to-charge ratio and retention time. Lipids were annotated with LipidMatch using data-dependent MS/MS and full-scan data.
  • Repeat extractions from the same donors on different days were analyzed using the same workflow and compared to assess reliability and reproducibility.
  • The authors report that DBS measurements may not be directly comparable with plasma or serum reference values; drying and storage, hematocrit, and spot volume are additional sources of variability. Volumetric DBS devices were used to collect a fixed 10 µL volume.

Clinical Implications

The authors state that specimen type and pre-analytical factors should be considered when interpreting DBS metabolite and lipid measurements, particularly when comparing them with plasma or serum reference values or when using non-volumetric cards. They report that clinical validation and further development are needed to assess the method’s potential for broader newborn screening and diagnostic use.

Conclusion

The described LC-HRMS/MS workflow enables metabolite and lipid profiling from a single 10 µL DBS. Its broader screening or diagnostic application remains to be assessed through further development and clinical validation.

Related Resources & Content

  1. The Analytical Scientist, 2026 — One Blood Spot, Two Omics Readouts
  2. The Analytical Scientist — One Blood Spot, Two Omics Readouts
  3. ASCO Publications — Integrating multi-omics features for blood-based multi-cancer early detection.
  4. ASCO Publications — Integrating multi-omics features for blood-based multi-cancer early detection.
  5. One Blood Spot, Two Omics Readouts
  6. HRSA Modernizes National Newborn Screening Review Process to Speed Up Evaluation of Emerging Conditions | HRSA
  7. Expanding Conditions for Newborn Screening-Findings from an Untargeted Metabolomics and Lipidomics Discovery Study.
  8. Expert consensus on the combined screening of genes and biomarkers for neonatal diseases

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

False

Advertisement

Recommended

False

Related Content

The Analytical Scientist Innovation Awards 2024: #7
Omics
The Analytical Scientist Innovation Awards 2024: #7

December 2, 2024

4 min read

Frank Steemers, co-founder and CSO of Scale Biosciences, tells us the story of ScalePlex – the 7th ranked innovation on this year’s Awards

The Analytical Scientist Innovation Awards 2024: #4
Omics
The Analytical Scientist Innovation Awards 2024: #4

December 5, 2024

6 min read

Thermo Fisher Scientific’s high-sensitivity mass spec for translational omics research – the Stellar MS – is ranked 4th in our annual Innovation Awards

Let Me See That Brain
Omics
Let Me See That Brain

December 9, 2024

1 min read

TRISCO sets a new standard for 3D RNA imaging, delivering high-resolution and uniform images to offer insights into brain function and anatomy

The Analytical Scientist Innovation Awards 2024
Omics
The Analytical Scientist Innovation Awards 2024

December 11, 2024

10 min read

Meet the products – and the experts – defining analytical innovation in 2024

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.